Skip to main content
SpringerLink
Log in

Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma

Treatment of stage II melanoma with viral lysates

  • Original Articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

A total of 80 patients with melanoma metastases in regional lymph nodes were treated by i.d. injections with a vaccine prepared from a vaccinia virus-infected allogeneic melanoma cell line; 39 patients have been followed for a 2-year period. Interim results from comparison of the treated group with 151 historical controls treated without the vaccine from September 1978 to December 1981 at the same institution and 56 non-randomized concurrent controls suggest that survival was significantly prolonged in the vaccinated group. At the 2-year period overall survival was 75% in the treated compared to 57% in the historical control group. Subset analysis showed a greater apparent benefit of vaccine therapy among patients who had metastases detected at the time of treatment of the primary melanoma (synchronous metastases), while therapy appeared less effective in patients with metastases detected at some time after treatment of the primary (delayed metastases). In the latter only those with one lymph node appeared to benefit from the treatment whereas in patients with synchronous metastases patients with three or more nodes as well as one node appeared to have improved survival. The survival rates at 2 years for treated patients with synchronous metastases in one, two, three or more lymph nodes was 100%, 83% and 79% respectively compared with that of 82%, 86% and 47% respectively in the equivalent control groups. Survival rates in treated patients with delayed metastases in one, two, three or more lymph nodes was 70%, 70% and 65% compared with 47%, 42% and 35% in the equivalent control groups. Treatment and control groups appeared well matched for a number of known prognostic features, including number and size of involved nodes, sex and thickness of primary tumor. Multivariate analysis indicated the effect of treatment was independent of these factors. Despite the empiricism of this approach the present results suggest that this form of therapy warrants further evaluation in a randomized controlled trial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aranha GV, McKhann CF, Grace TB, Gunnarsson A, Simmons RL (1979) Adjuvant immunotherapy of malignant melanoma. Cancer 43:1297

    Google Scholar 

  2. Austin FC, Boon CW (1979) Virus augmentation of the antigenicity of tumor cell extracts. Adv Cancer Res 30:301

    Google Scholar 

  3. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA (1981) A multifactorial analysis of melanoma. III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 193:377

    Google Scholar 

  4. Balch CM, Soong SJ, Shaw HM, Milton GW (1985) An analysis of prognostic factors in 4000 patients with cutaneous melanoma. In: Cutaneous melanoma. J. B. Lippincott Co, Philadelphia, p 338

    Google Scholar 

  5. Balch CM, Urist MM, Maddox WA, Milton GW, McCarthy WH (1985) Management of regional metastatic melanoma. In: Balch CM, Milton GW (eds) Cutaneous melanoma, clinical management and treatment resuluts worldwide J B. Lippincott Co, Philadelpha, p 93

    Google Scholar 

  6. Bukowski RM, Deodhar S, Newlett JS, Greenstreet R (1983) Randomized controlled trial of transfer factor in stage II malignant melanoma. Cancer 51:269

    Google Scholar 

  7. Burdick KH, Hawk WA (1964) Vitiligo in a case of vaccinia virus-treated melanoma. Cancer 17:708

    Google Scholar 

  8. Cahan LD, Irie RF, Singh R, Cassidenti A, Paulson JC (1982) Identification of a human neuroectodermal tumor antigen (OFA-1–2) as ganglioside GD2. Proc Natl Acad Sci USA 79:7629

    Google Scholar 

  9. Camacho ES, Pinksky CM, Braun DW, Golbey RB, Fortner JG, Wanebo HJ, Oettgen HF (1981) DNCB reactivity and prognosis in 419 patients with malignant melanoma. Cancer 47:2446

    Google Scholar 

  10. Cascinelli N, Vaglini M, Nava M, Santinami M, Marolda R, Rovini D, Clemente C, Bufalino R, Morabito A (1984) Prognosis of skin melanoma with regional node metastases. J Surg Oncol 25:240

    Google Scholar 

  11. Cassel WA, Murray DR, Phillips HS (1983) A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer 52:856

    Google Scholar 

  12. Cox DR (1972) Regression model and life tables. J Royal Stat Soc B34:187

    Google Scholar 

  13. Dales S, Oldstone MBA (1982) Localization at high resolution of antibody-induced mobilization of vaccinia virus hemagglutinin and the major histocompatibility antigens on the plasma membrane of infected cells. J Exp Med 156:1435

    Google Scholar 

  14. Eilber FR, Townsend CM, Morton DL (1976b) Results of BCG adjuvant immunotherapy for melanoma of the head and neck. Am J Surg 132:476

    Google Scholar 

  15. Everall JD, Wand J, O'Doherty CJ, Dowd PM (1975) Treatment of primary melanoma by intralesional vaccinia before excision. Lancet II:583

    Article  Google Scholar 

  16. Freedman RS, Bowen JM, Herson J, Wharton JT, Rutledge FN, Hamberger AD (1980) Virus modified homologous tumor-cell extract in the treatment of vulvar carcinoma. Cancer Immunol Immunother 8:33

    Google Scholar 

  17. Freedman RS, Rutledge FN, Wharton JT (1983) Adjunctive immunotherapy with virus modified tumor cell extract in patients with high risk squamous carcinoma of the uterine cervix. Am J Clin Oncol Cancer Clin Trials 6:155

    Google Scholar 

  18. Gehan EA, Frereich EJ (1974) Non randomized controls in cancer clinical trials. N Engl J Med 290:198

    Google Scholar 

  19. Gutterman JU, Richman SP, McBride CM, Burgess MA, Bartold SL, Kennedy A, Gehan EA, Mavlight G, Hersh EM (1979) Immunotherapy for recurrent malignant melanoma. Efficacy of BCG in prolonging the postoperative disease free interval and survival. Recent Results Cancer Res 68:359

    Google Scholar 

  20. Hersey P (1985) Review of melanoma antigens recognized by monoclonal antibodies. Their functional significance and applications in diagnosis and treatment of melanoma. Pathology 17:346

    Google Scholar 

  21. Hersey P, Balch CM (1984) Current status and future prospects for adjuvant therapy of melanoma. Aust NZ J Surg 54:303

    Google Scholar 

  22. Hersey P, Edwards A, Murray E, McCarthy WH, Milton GW (1983) Prognostic significance of leukocyte dependent antibody activity in melanoma patients. J Natl Cancer Inst 71:45

    Google Scholar 

  23. Hersey P, Edwards A, D'Alessandro G, MacDonald M (1986) Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. II. Effects on cell mediated cytotoxicity and leukocyte dependent antibody activity. Cancer Immunol Immunother 22:221

    Google Scholar 

  24. Hilal EY, Pinksky CM, Hirshaut Y, Wanebo HJ, Hansen JA, Braun DW, Fortner JG, Oettgen HF (1981) Surgical adjuvant therapy of malignant melanoma with Corynebacterium parvum. Cancer 48:245

    Google Scholar 

  25. Hill GJ, Moss S, Fletcher W, Golomb F, Grace T (1978) DTIC melanoma adjuvant study. Final report. Proc Am Assoc Cancer Res 19:309

    Google Scholar 

  26. Jones PC, Sze LL, Liu PY, Morton DL, Irie RF (1981) Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 66:249

    Google Scholar 

  27. Lotzova E, Savary CA, Freedman RS, Bowen JM (1984) Natural killer cell cytotoxic potential of patients with ovarian carcinoma and its modulation with virus-modified tumor cell extract. Cancer Immunol Immunother 17:124

    Google Scholar 

  28. Milton GW (1963) Some methods used in the management of metastatic melanoma. Aust J Dermatol 7:15

    Google Scholar 

  29. Mallon V, Domber EA, Holowczak JA (1985) Vaccinia virus proteins on the plasma membranes of infected cells. II. Expression of viral antigens and killing of infected cells by vaccinia virus-specific cytotoxic T cells. Virology 145:1–23

    Google Scholar 

  30. Muir PD, Gunz FW (1979) A cytogenetic study of eight human melanoma cell lines. Pathology 11:597–606

    Google Scholar 

  31. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1

    CAS  PubMed  Google Scholar 

  32. Pope JH, Morrison L, Moss DJ, Parsons PG, Sr. Regius Mary (1979) Human malignant melanoma cell lines. Pathology 11:191

    Google Scholar 

  33. Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ (1982) GD3, a prominent ganglioside of human melanoma. J Exp Med 155:1133

    Google Scholar 

  34. Roenigk HH, Deodhar S, St. Jacques R, Burdick K (1974) Immunotherapy of malignant melanoma with vaccinia virus. Arch Dermatol 109:668

    Google Scholar 

  35. Roses DF, Provet JA, Harris MN, Gumport SL, Dubin N (1985) Prognosis of patients with stage II cutaneous malignant melanoma Ann Surg 201:103

    Google Scholar 

  36. Sacks H, Chalmers TC, Smith H (1982) Randomized versus historical controls for clinical trials. Am J Med 72:233

    Google Scholar 

  37. Shimizu Y, Fujiwara H, Ueda S, Wakamiya N, Kato S, Hamaoka T (1984) The augmentation of tumor specific immunity by virus help. II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus reactive helper T cells. Eur J Immunol 14:839–843

    Google Scholar 

  38. Sinkovics JG, Papadopoulos NE, Plager G (1981) Viral oncolysate in immunotherapy of human tumors. In: Advances in comparative leukemia research on leukemia and related diseases. Elsevier, North Holland Inc, NY, p 613

    Google Scholar 

  39. Veronesi U, Adamua J, Aubert C et al. (1982) WHO study group trial No. 6. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 307:913

    Google Scholar 

  40. Wallack MK (1981) Specific immunotherapy with vaccinia oncolysates. Cancer Immunol Immunother 12:1

    Google Scholar 

  41. Wallack MK, Michaelides M (1984) Serologic responses to human melanoma lines from patients with melanoma undergoing treatment with vaccinia melanoma cell lysates. Surgery 96:791

    Google Scholar 

  42. Wallack MK, Steplewski Z, Koprowski H, Rosato E, George J, Hulihan B, Johnson J (1977) A new approach in specific, active immunotherapy. Cancer 39:560

    Google Scholar 

  43. Watanabe T, Pukel CS, Takeyama H, Lloyd KO, Shiku H, Li LTC, Travassos LR, Oettgen HF, Old LJ (1982) Human melanoma antigen AH is an autoantigenic ganglioside related to GD2. J Exp Med 156:1884

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sydney Melanoma Unit, Department of Surgery, University of Sydney at Royal Prince Alfred Hospital, 2050, Camperdown, N.S.W, Australia

    Peter Hersey, Anne Edwards, Helen Shaw, William McCarthy & Gerald Milton

  2. Ludwig Institute for Cancer Research (Sydney Branch) University of Sydney, 2006, N.S.W., Australia

    Alan Coates

Authors
  1. Peter Hersey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne Edwards
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alan Coates
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Helen Shaw
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. William McCarthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gerald Milton
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hersey, P., Edwards, A., Coates, A. et al. Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Cancer Immunol Immunother 25, 257–265 (1987). https://doi.org/10.1007/BF00199156

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00199156

Keywords

Search

Navigation